Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda approval symbols : SNY save search
Viatris is First to Receive FDA Approval of Generic Restasis® (Cyclosporine Ophthalmic Emulsion 0.05%) to Treat Dry Eye Disease
Published: 2022-02-03 (Crawled : 23:00) - prnewswire.com
VTRS | News A | $11.55 1.67% 1.65% 7.2M
|
Health Technology
|
| O: -1.05%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -2.48%
H: 0.0%
C: 0.0%
restasis dry eye fda eye fda approval eye disease approval disease ophthalmic emulsion
Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full U.S. FDA Approval for Individuals 16 Years and Older
Published: 2021-08-23 (Crawled : 16:00) - globenewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: 3.22%
H: 2.13%
C: -0.72%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.28%
H: 0.09%
C: -0.59%
BNTX | News | $88.18 -0.35% -0.35% 280K
|
Health Technology
|
| O: 7.12%
H: 3.88%
C: 2.3%
covid fda fda approval vaccine approval comirnaty® order
Muscular Dystrophy Association Celebrates FDA Approval of (Nexviazyme) for Treatment of Pompe disease
Published: 2021-08-06 (Crawled : 21:00) - prnewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
| Email alert
Add to watchlist
disease treatment fda fda approval approval
FDA approves Nexviazyme® (avalglucosidase alfa-ngpt), an important new treatment option for late-onset Pompe disease
Published: 2021-08-06 (Crawled : 16:00) - globenewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.26%
H: 0.0%
C: 0.0%
disease treatment fda fda approval
New Day For Diabetes Patients As FDA Approves First-Ever Interchangeable Biosimilar
Published: 2021-07-29 (Crawled : 14:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.69%
H: 0.08%
C: -0.33%
diabetes fda fda approval biosimilar
New Day For Diabetes Patients As FDA Approves First-Ever Interchangeable Bios...
Published: 2021-07-29 (Crawled : 14:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.69%
H: 0.08%
C: -0.33%
diabetes fda fda approval
Ligand’s Partner Merck Receives FDA Approval for VAXNEUVANCE™ for the Prevention of Invasive Pneumococcal Disease in Adults Caused by 15 Serotypes
Published: 2021-07-19 (Crawled : 13:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.68%
H: 0.41%
C: -0.31%
LGND | $70.87 1.4% 1.38% 150K
|
Health Technology
|
| O: -5.38%
H: 8.88%
C: 8.3%
disease fda fda approval approval pneumococcal
FDA approves isatuximab-irfc for multiple myeloma
Published: 2021-06-11 (Crawled : 12:53) - fda.gov
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.13%
H: 0.11%
C: -0.09%
fda approval fda approval
Zealand Pharma receives first FDA approval and prepares for launch of Zegalogue® (dasiglucagon) injection
Published: 2021-05-12 (Crawled : 13:15) - globenewswire.com
ZEAL | $17.59 1.21% -4.21%
|
Health Technology
|
| O: -2.05%
H: 0.17%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.46%
H: 0.95%
C: 0.12%
fda fda approval injection approval pharma
Pfizer and BioNTech Initiate Rolling Submission of Biologics License Application for U.S. FDA Approval of their COVID-19 Vaccine
Published: 2021-05-07 (Crawled : 11:00) - globenewswire.com
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -0.36%
H: 2.09%
C: 1.36%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.92%
H: 0.88%
C: 0.66%
BNTX | News | $88.18 -0.35% -0.35% 280K
|
Health Technology
|
| O: 9.13%
H: 1.36%
C: 0.2%
covid fda fda approval vaccine license approval submission application
FDA approves isatuximab-irfc for multiple myeloma
Published: 2021-04-01 (Crawled : 11:49) - fda.gov
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.22%
H: 0.51%
C: 0.02%
fda approval fda approval
FDA approves Sarclisa® (isatuximab-irfc) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma
Published: 2021-03-31 (Crawled : 23:00) - prnewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.22%
H: 0.51%
C: 0.02%
fda fda approval
FDA approves Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma
Published: 2021-03-31 (Crawled : 22:00) - globenewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.22%
H: 0.51%
C: 0.02%
fda fda approval
After Head-to-Head Study with Sanofi Drug, FDA Approves Janssen’s Relapsing Multiple Sclerosis Drug
Published: 2021-03-19 (Crawled : 16:00) - biospace.com/
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.14%
H: 0.5%
C: -0.4%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.81%
H: 0.99%
C: 0.83%
multiple sclerosis fda drug sclerosis fda approval approval
After Head-to-Head Study with Sanofi Drug, FDA Approves Janssen’s Relapsing M...
Published: 2021-03-19 (Crawled : 16:00) - biospace.com/
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.14%
H: 0.5%
C: -0.4%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.81%
H: 0.99%
C: 0.83%
fda drug fda approval approval
Janssen Announces U.S. FDA Approval of PONVORY™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
Published: 2021-03-19 (Crawled : 12:30) - prnewswire.com
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.14%
H: 0.5%
C: -0.4%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.81%
H: 0.99%
C: 0.83%
multiple sclerosis treatment fda fda approval sclerosis approval train
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.